Attenuated stress-induced catecholamine release in mice lacking the vasopressin V1b receptor.

Vasopressin V(1b) receptor is specifically expressed in the pituitary and mediates adrenocorticotropin release, thereby regulating stress responses via its corticotropin releasing factor-like action. In the present study we examined catecholamine release in response to two types of stress in mice lacking the V(1b) receptor gene (V(1b)R(-/-) mice) vs. wild-type mice. There were no significant differences in the basal plasma levels of catecholamines between the two genotypes. In response to stress induced by forced swimming, norepinephrine (NE), but not epinephrine (E) or dopamine (DA), was increased in wild-type mice, whereas the increases in NE and DA were not observed in V(1b)R(-/-) mice. In wild-type mice, E, but not NE or DA, was increased in response to social isolation stress, whereas the increase in E was not observed in V(1b)R(-/-) mice. These results suggest that the V(1b) receptor regulates stress-induced catecholamine release. Because it has been suggested that arginine-vasopressin (AVP) is related to the development of depression, we also evaluated immobility time in the forced swimming test, and we found no significant change in V(1b)R(-/-) mice. Taken together, these findings suggest that, in addition to the previously elucidated effect on the hypothalamic-pituitary-adrenal axis, vasopressin activity via V(1b) receptors regulates stress-induced catecholamine release.

[1]  G. Tsujimoto,et al.  Disruption of the Prepulse Inhibition of the Startle Reflex in Vasopressin V1b Receptor Knockout Mice: Reversal by Antipsychotic Drugs , 2005, Neuropsychopharmacology.

[2]  G. Tsujimoto,et al.  The vasopressin V1b receptor critically regulates hypothalamic-pituitary-adrenal axis activity under both stress and resting conditions. , 2004, The Journal of clinical investigation.

[3]  G. Griebel,et al.  Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[4]  G. Griebel,et al.  Characterization of (2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a selective and orally active vasopressin V1b receptor antagonist. , 2002, The Journal of pharmacology and experimental therapeutics.

[5]  J. Burbach,et al.  Immunohistochemical localization of the vasopressin V1b receptor in the rat brain and pituitary gland: anatomical support for its involvement in the central effects of vasopressin. , 2001, Endocrinology.

[6]  G. Smith,et al.  CRF type I receptor-deficient mice exhibit a pronounced pituitary-adrenal response to local inflammation. , 1999, Endocrinology.

[7]  G. Koob,et al.  Corticotropin Releasing Factor Receptor 1–Deficient Mice Display Decreased Anxiety, Impaired Stress Response, and Aberrant Neuroendocrine Development , 1998, Neuron.

[8]  G. Guillon,et al.  Molecular and functional characterization of V1b vasopressin receptor in rat adrenal medulla. , 1996, Endocrinology.

[9]  X. Bertagna,et al.  Cloning and characterization of the human V3 pituitary vasopressin receptor , 1994, FEBS letters.

[10]  J. P. Schwartz,et al.  Increase in Rat Adrenal Phenylethanolamine N‐Methyltransferase mRNA Level Caused by Immobilization Stress Depends on Intact Pituitary ‐ Adrenocortical Axis , 1994, Journal of neurochemistry.

[11]  F. Antoni Vasopressinergic Control of Pituitary Adrenocorticotropin Secretion Comes of Age , 1993, Frontiers in Neuroendocrinology.

[12]  Michael J. Brownstein,et al.  Cloning and characterization of a vasopressin V2 receptor and possible link to nephrogenic diabetes insipidus , 1992, Nature.

[13]  M. Brownstein,et al.  Molecular cloning and expression of a rat Via arginine vasopressin receptor , 1992, Nature.

[14]  E. T. Segura,et al.  Repeated (isolation) stress increases tribulin-like activity in the rat , 1989, Cellular and Molecular Neurobiology.

[15]  M. Thibonnier Vasopressin and blood pressure. , 1988, Kidney international. Supplement.

[16]  A. F. Muller,et al.  Vasopressin antagonists allow demonstration of a novel type of vasopressin receptor in the rat adenohypophysis. , 1986, Molecular pharmacology.

[17]  R. Porsolt,et al.  Behavioral despair in mice: a primary screening test for antidepressants. , 1977, Archives internationales de pharmacodynamie et de therapie.

[18]  S. Sasaki,et al.  Molecular mechanisms and drug development in aquaporin water channel diseases: molecular mechanism of water channel aquaporin-2 trafficking. , 2004, Journal of pharmacological sciences.

[19]  E. Ginns,et al.  Vasopressin V1b receptor knockout reduces aggressive behavior in male mice , 2002, Molecular Psychiatry.

[20]  E. Widmaier,et al.  Impaired basal and restraint-induced epinephrine secretion in corticotropin-releasing hormone-deficient mice. , 2000, Endocrinology.

[21]  F. Holsboer,et al.  Selective activation of the hypothalamic vasopressinergic system in mice deficient for the corticotropin-releasing hormone receptor 1 is dependent on glucocorticoids. , 2000, Endocrinology.

[22]  G. Guillon,et al.  Regulation of Adrenocortical Function by Vasopressin , 1998, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[23]  F. Goodwin,et al.  Neurohypophyseal function in affective illness. , 1983, Psychopharmacology bulletin.